Algorithm Intestinal crypts Dysbiose Contraindication Helicobacter pylori Safety Methylation Colon IBD Inflammatory Bowel Diseases Disease Progression Effectiveness Venous thromboembolism Gene expression Ulcerative colitis RISK Ustekinumab Thérapie ciblée IL23 Disease progression Anti-TNF agents 18 FDG-PET/CT PCR Consensus Biomarker DNA methylation Small molecules Colorectal cancer Anti-TNF Disability Eradication Immunosuppressant Colectomy T1118 translocation Heart disease risk factors Cost effectiveness Patients experience Gènes Inclusion Inflammatory bowel diseases Crohn's disease Fecal microbiota Microbiota Tuberculosis Stricture Tailored therapy Bacteria Therapeutics Neoadjuvant chemotherapy Monitoring Patient-reported outcome Acceptability Upper gastrointestinal tract MALT Cancer Vedolizumab Drug Primary sclerosing cholangitis Microbiote Clinical guidelines DNA METHYLATION MICROBIOTA Rituximab plus chlorambucil Original Article Clinical Inflammatory bowel disease HIV Maintenance therapy Bactéries Genes Inhibitor Colon cancer Clinical trial Over 80s MARKER Screening Alkylating agents Crohn’s disease Survival Kidney diseases Cell adhesion Biologics Endoscopic treatment MORTALITY Parvimonas micra Surgery Epigenetics Gene methylation Colonic epithelial primary cells COLON-CANCER IL12 Colorectal cancer Colibactin and lipids Résistance Méthylation Rituximab Dysbiosis Resistance Epigénétiques Immune cells Eligibility CARCINOGENESIS